NEW YORK (dpa-AFX) – The analysis house Jefferies has left Novo Nordisk “underperform” with a price target of 270 Danish crowns based on figures and outlook. The pharmaceutical company’s new adjusted outlook for 2026 as well as the changes in management are likely to weigh heavily on the stock, wrote Michael Leuchten in his reaction on Tuesday. The sales target will probably cause the consensus estimate to fall in the high single-digit percentage range. The adjusted earnings outlook even threatens to reduce the corresponding forecast by a low double-digit range. The surprisingly good sales development in the last quarter is based on special factors and is likely to be overshadowed by a clearly deteriorated gross margin./rob/gl/he
Publication of the original study: 02/03/2026 / 1:13 p.m. / time zone not specified in the study. First time distribution of the original study: 02/03/2026 / 1:13 p.m. / time zone not specified in the study
